CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD). Despite the efficacy of ibrutinib in treating relapsed/refractory mantle cell lymphoma, the obstacle of residual cells contributes to relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuhr, Viktoria, Heidenreich, Shanice, Srivastava, Mugdha, Riedel, Angela, Düll, Johannes, Gerhard-Hartmann, Elena, Rosenwald, Andreas, Rauert-Wunderlich, Hilka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805448/
https://www.ncbi.nlm.nih.gov/pubmed/36587029
http://dx.doi.org/10.1038/s41420-022-01289-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805448/
https://www.ncbi.nlm.nih.gov/pubmed/36587029
http://dx.doi.org/10.1038/s41420-022-01289-7

Ejemplares similares